Active pharmaceutical ingredients (APIs) produced at Divi Laboratories Ltd., of Chippada Village, India, were put on import alert nearly four months after officials at the facility refused to provide FDA investigators with the original, unmodified audit trail data from Divi's chromatographic systems used to test APIs for the U.S. market.